1. Home
  2. ONDS vs NUVB Comparison

ONDS vs NUVB Comparison

Compare ONDS & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ondas Holdings Inc.

ONDS

Ondas Holdings Inc.

BUY

Current Price

$8.54

Market Cap

2.8B

ML Signal

BUY

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$9.37

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONDS
NUVB
Founded
2014
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.9B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ONDS
NUVB
Price
$8.54
$9.37
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
8
Target Price
$10.00
$10.63
AVG Volume (30 Days)
76.5M
6.0M
Earning Date
11-13-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$24,748,922.00
$26,748,000.00
Revenue This Year
$417.68
$609.55
Revenue Next Year
$244.11
$197.91
P/E Ratio
N/A
N/A
Revenue Growth
208.40
1137.19
52 Week Low
$0.57
$1.54
52 Week High
$11.70
$9.75

Technical Indicators

Market Signals
Indicator
ONDS
NUVB
Relative Strength Index (RSI) 51.84 69.97
Support Level $8.67 $9.06
Resistance Level $9.84 $9.75
Average True Range (ATR) 0.91 0.48
MACD -0.01 -0.01
Stochastic Oscillator 47.48 82.31

Price Performance

Historical Comparison
ONDS
NUVB

About ONDS Ondas Holdings Inc.

Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Share on Social Networks: